Fatty liver disease, an emerging etiology of hepatocellular carcinoma in Argentina

Table 4 Baseline pre-treatment variables associated with 5-year mortality, univariate cox regression

Variable	5-yr mortality rate, (%)	Hazard ratio (95%CI)	P value
Age (yr)		1.02 (1.01; 1.04)	< 0.0001
Gender: male (n = 537)	42.7	1.08 (0.83; 1.42)	0.58
Female (n = 170)	42.3
Comorbidity
Yes (n = 299)	45.1	1.08 (0.86; 1.37)	0.49
No (n = 409)	40.6
Diabetes mellitus
Yes (n = 196)	38.8	0.83 (0.63; 1.08)	0.17
No (n = 512)	44
NAFLD
Yes (n = 81)	35.9	1.16 (0.81; 1.69)	0.41
No (n = 627)	56.9
ECOG 0-2
Yes (n = 637)	37.9	0.19 (0.14; 0.26)	0.0001
No (n = 71)	84.5
BCLC 0-A
Yes (n = 335)	26	0.29 (0.23; 0.38)	0.0001
No (n = 373)	57.4
Cirrhosis
Yes (n = 639)	42.9
No (n = 69)	39.1	0.86 (0.58; 1.28)	0.45
Child Pugh
A (n = 352)	34.5	-
B (n = 238)	41.6	1.38 (1.06; 1.83)	0.019
C (n = 118)	68.6	3.23 (2.41; 4.34)	0.0001
Clinically significant portal hypertension
Yes (n = 484)	40.2	1.22 (0.94; 1.57)	0.13
No (n = 224)	43.7
AFP > 1000 ng/mL
Yes (n = 106)	64.1	3.09 (2.31; 4.15)	0.0001
No (n = 569)	39.5
Tumor vascular invasion
Yes (n = 74)	77	4.74 (3.48; 6.44)	0.0001
No (n = 634)	38.5
Extrahepatic tumor disease
Yes (n = 48)	70.8	3.29 (2.25; 4.81)	0.0001
No (n = 660)	40.5

Normal Values: Alpha-fetoprotein 0.6-4.4 ng/mL. AFP: Alpha-fetoprotein; BCLC: Barcelona clinic liver cancer; ECOG: Eastern cooperative oncology group; HCC: Hepatocellular carcinoma; LT: Liver transplantation; WL: Waiting list; NAFLD: Non-alcoholic fatty liver disease.